Risk of cervical cancer and squamous intraepithelial lesions according to human papillomavirus high-risk serotypes detected by qualitative real-time in vitro PCR

Purpose of investigation: To establish the relationship between high-risk human papillomavirus (hrHPV) serotypes and the odds of developing cervical intraepithelial lesions. Material and Methods: Retrospective cohort study using altered cervical cytology results and hrHPV test obtained by PCR. Groups were divided according to low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) and squamous cervical cancer (SCC) results, while hrHPV was divided according to polymerase chain reaction (PCR) results in “other HR-HPV, HPV-16, and HPV-18. Logistic regression analysis was performed to estimate the odds of each hrHPV serotype in developing squamous intraepithelial lesions or SCC. Results: A total of 252 samples were analysed, mean age was 42 ± 12.65 years. Prevalence of hrHPV infection was 60% (n=152). “Other HR-HPV” group was the most common infection in our population (39%); nonetheless, there were no increased odds for any HPV group and the risk for developing LSIL. The odds for HSIL were 4.58 and 7 for “other HR-HPV” and HPV-16, respectively. Odds for SCC were 11.29 and 7.35 for HPV-18 and HPV-16. There were no significant odds in HPV-18 for HSIL and “other HR-HPV” SCC. Conclusion: The present authors found a greater prevalence for “other HR-HPV” group in this population. Nonetheless, HPV-16 and HPV-18 contribute the highest probability of developing HSIL and SCC.

Human papillomavirus; HPV; Prevalence; LSIL; HSIL; Cervical carcinoma

[1] Mukakalisa I., Bindler R., Allen C., Dotson J.: “Cervical cancer in developing countries: effective screening and preventive strategies with an application in Rwanda”. Health. Care. Women. Int., 2014, 35, 1065.

[2] Soler M.E., Gaffikin L., Blumenthal P.D.: “Cervical cancer screening in developing countries”. Prim. Care. Update. Ob. Gyns., 2000, 7, 118.

[3] Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., et al.: “Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012”. Int. J. Cancer, 2015, 136, E359.

[4] Plummer M., de Martel C., Vignat J., Ferlay J., Bray F., Franceschi S.: “Global burden of cancers attributable to infections in 2012: a synthetic analysis”. Lancet. Glob. Health, 2016, 4, e609.

[5] Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al.: “Human papillomavirus is a necessary cause of invasive cervical cancer worldwide”. J. Pathol., 1999, 189, 12.

[6] Orth G., Favre M., Croissant O.: “Characterization of a new type of human papillomavirus that causes skin warts”. J. Virol., 1977, 24, 108.

[7] Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al.: “Epidemiologic classification of human papillomavirus types associated with cervical cancer”. N. Engl. J. Med., 2003, 348, 518.

[8] Clifford G.M., Smith J.S., Aguado T., Franceschi S.: “Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis”. Br. J. Cancer, 2003, 89, 101.

[9] Coser J., Boeira Tda.R., Wolf J.M., Cerbaro K., Simon D., Lunge V.R.: “Cervical human papillomavirus infection and persistence: a clinic-based study in the countryside from South Brazil”. Braz. J. Infect. Dis., 2016, 20, 61.

[10] Longatto-Filho A., Erzen M., Branca M., Roteli-Martins C., Naud P., Derchain S.F., et al.: “Human papillomavirus testing as an optional screening tool in low-resource settings of Latin America: experience from the Latin American Screening study”. Int. J. Gynecol. Cancer, 2006, 16, 955.

[11] Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al.: “Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer”. N. Engl. J. Med., 2007, 357, 1579.

[12] Massad L.S., Einstein M.H., Huh W.K., Katki H.A., Kinney W.K., Schiffman M., et al.: “2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors”. Obstet. Gynecol., 2013, 121, 829.

[13] WHO Guidelines Approved by the Guidelines Review Committee.: “WHO Guidelines for Screening and Treatment of Precancerous Lesions for Cervical Cancer Prevention-2”. Geneva, 2013.

[14] Solomon D., Davey D., Kurman R., Moriarty A., O’Connor D., Prey M., et al.: “The 2001 Bethesda System: terminology for reporting results of cervical cytology”. JAMA, 2002, 287, 2114.

[15] “Cervical cancer screening: quick reference guide, endocervical brush/spatula protocol”. Available at: http://wwwthinprepcom/hcp/ indexhtml.

[16] “Hologic, Inc. ThinPrep® 2000 system”. Avaliable at: http://wwwthinprepcom/pdfs/thinprep_package_insertpdf

[17] “Roche Molecular Systems, Inc”. Available at: http://wwwaccess- datafdagov/cdrh_docs/pdf10/p100020cpdf

[18] Bruni L., Diaz M., Castellsague X., Ferrer E., Bosch F.X., de Sanjose S.: “Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings”. J. Infect. Dis., 2010, 202, 1789.

[19] Mu Mu S., Harano T., Okada S., Aye Aye W., Khin Saw A., Hlaing Myat T., et al.: “Prevalence of high-risk human papillomavirus (HRHPV) infection among women with normal and abnormal cervical cytology in Myanmar”. Acta. Med. Okayama, 2014, 68, 79.

[20] Hammouda D., Clifford G.M., Pallardy S., Ayyach G., Chekiri A., Boudrich A., et al.: “Human papillomavirus infection in a population-based sample of women in Algiers, Algeria”. Int. J. Cancer., 2011, 128, 2224.

[21] Smith J.S., Lindsay L., Hoots B., Keys J., Franceschi S., Winer R., et al.: “Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update”. Int. J. Cancer, 2007, 121, 621.

[22] Martinez-Portilla R.J., Lopez-Velazquez J.L., Martinez-Rojas G.C., Aguilar-Villagomez M.I., De la Torre-Rendon F.E, Villafan-Bernal J.R.: “Prevalence of HPV high-risk serotypes detected by PCR in patients with normal cervical cytology at the Hospital Regional Adolfo Lopez Mateos, ISSSTE”. Ginecol. Obstet. Mex., 2016, 84, 556.

[23] Xu H., Lin A., Shao X., Shi W., Zhang Y., Yan W.: “Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China”. Oncotarget, 2016, 7, 83775.

[24] Kay P., Soeters R., Nevin J., Denny L., Dehaeck C.M., Williamson A.L.: “High prevalence of HPV 16 in South African women with cancer of the cervix and cervical intraepithelial neoplasia”. J. Med. Virol., 2003, 71, 265.

[25] Ghosh A.K., Smith N.K., Stacey S.N., Glew S.S., Connor M.E., Arrand J.R., et al.: “Serological response to HPV 16 in cervical dysplasia and neoplasia: correlation of antibodies to E6 with cervical cancer”. Int. J. Cancer., 1993, 53, 591.